Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
McKinsey
Harvard Business School
Mallinckrodt
Medtronic

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for VX-661

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for VX-661?

VX-661 is an investigational drug.

There have been 32 clinical trials for VX-661. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2018.

The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and [disabled in preview]. The leading clinical trial sponsors are Vertex Pharmaceuticals Incorporated and [disabled in preview].

There are fifty-nine US patents protecting this investigational drug and six hundred and twenty-two international patents.

Recent Clinical Trials for VX-661
TitleSponsorPhase
Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and OlderVertex Pharmaceuticals IncorporatedPhase 3
Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyVertex Pharmaceuticals IncorporatedPhase 3
A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508delVertex Pharmaceuticals IncorporatedPhase 3

See all VX-661 clinical trials

Clinical Trial Summary for VX-661

Top disease conditions for VX-661
Top clinical trial sponsors for VX-661

See all VX-661 clinical trials

US Patents for VX-661

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
VX-661   Start Trial Compounds, compositions, and methods for increasing CFTR activity Proteostasis Therapeutics, Inc. (Boston, MA)   Start Trial
VX-661   Start Trial Modulators of ATP-binding cassette transporters Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
VX-661   Start Trial Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6- -fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
VX-661   Start Trial Process of producing cycloalkylcarboxamido-indole compounds Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
VX-661   Start Trial Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
VX-661   Start Trial Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-- fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxa- mide Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
VX-661   Start Trial Modulators of cystic fibrosis transmembrane conductance regulator protein AbbVie S.a.r.l. (Luxembourg, LU) Galapagos NV (Mechelen, BE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for VX-661

Drugname Country Document Number Estimated Expiration Related US Patent
VX-661 Australia 2015229117 2034-03-13   Start Trial
VX-661 Canada 2942387 2034-03-13   Start Trial
VX-661 European Patent Office 3116870 2034-03-13   Start Trial
VX-661 World Intellectual Property Organization (WIPO) 2015138934 2034-03-13   Start Trial
VX-661 Australia 2007235260 2026-04-07   Start Trial
VX-661 Brazil PI0710965 2026-04-07   Start Trial
VX-661 Canada 2648719 2026-04-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Colorcon
Boehringer Ingelheim
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.